Table 3.
Arsenic species in amniotic fluid (AF) and maternal plasma of APL patients treated with arsenic trioxide in pregnancy.
| Patients | Sample time | Concentration (ng/ml) | Ratio(CAF/CMP); | ||
|---|---|---|---|---|---|
| Maternal plasma (CMP) | Amniotic fluid (CAF) | ||||
| P1 | 4 days after the end of induction therapy | iAs | 3.56 | 5.81 | 1.63 |
| DMA | 9.29 | 11.71 | 1.26 | ||
| MMA | 8.07 | 4.79 | 0.59 | ||
| tAs | 20.92 | 22.31 | 1.07 | ||
| PMI | 2.27 | 0.82 | / | ||
| SMI | 1.15 | 2.44 | / | ||
| iAs% | 17.02 | 26.04 | / | ||
| DMA% | 44.41 | 52.49 | / | ||
| MMA% | 38.58 | 21.47 | / | ||
| P2 | 6 days after the end of induction therapy | iAs | 2.20 | 5.60 | 2.55 |
| DMA | 7.68 | 6.25 | 0.81 | ||
| MMA | 6.15 | 2.34 | 0.38 | ||
| tAs | 16.03 | 14.19 | 0.89 | ||
| PMI | 2.80 | 0.42 | / | ||
| SMI | 1.25 | 2.67 | / | ||
| iAs% | 13.72 | 39.46 | / | ||
| DMA% | 47.91 | 44.05 | / | ||
| MMA% | 38.37 | 16.49 | / | ||
CAF/CMP, AF concentration/maternal plasma concentration; iAs, inorganic arsenic; MMA, monomethylarsonic acid; DMA, dimethylarsinic acid; tAs, total arsenic, tAs = iAs + DMA + MMA. Percentage (%). (Concentrations of arsenic species/Concentration of tAs) × 100%. PMI, primary methylation index (MMA/iAs); SMI, secondary methylation index (DMA/MMA).